|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|

|  |  |  |
| --- | --- | --- |
|

|  |  |
| --- | --- |
|

|  |
| --- |
|  |

 |

 |
|

|  |  |  |  |
| --- | --- | --- | --- |
|

|  |  |  |
| --- | --- | --- |
|

|  |
| --- |
| Community Pharmacy England logo |

|  |
| --- |
| **Newsletter**30th August 2024 |

 |

 |

 |
|

|  |  |
| --- | --- |
|

|  |
| --- |
| The voice of community pharmacy (banner) |

 |
|

|  |  |
| --- | --- |
|

|  |
| --- |
| **This newsletter - sent on Mondays, Wednesdays and Fridays - contains important information and resources to support community pharmacies across England.** |

 |

 |
|

|  |
| --- |
|  |

 |
|

|  |  |
| --- | --- |
|

|  |
| --- |
| **In this update: Pharmacy First thresholds; Rivaroxaban tablets reimbursement; Restrictions on puberty blockers extended; MHRA Webinar on Windsor Framework.** |

 |

 |
|

|  |
| --- |
|  |

 |
|

|  |  |
| --- | --- |
|

|  |
| --- |
| **Pharmacy First thresholds**The ability of pharmacy owners to achieve the thresholds for the monthly Pharmacy First payment has been a topic of great concern for pharmacy owners and Community Pharmacy England. Following representations by Community Pharmacy England [Ministers agreed to make an adjustment for August](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=541ef2a58e&e=d19e9fd41c) but there have been no further updates since then. This means that, as things stand, the Pharmacist First threshold will be increasing to 20 clinical pathway consultations for the month of September. It is our strongly held view that community pharmacy has carried out its side of the bargain in launching the Pharmacy First service, but NHS England need to match that commitment through more effective advertising and ensuring that GPs refer as many patients as possible. |

 |

 |

|  |  |
| --- | --- |
|

|  |
| --- |
|  |

 |
|

|  |
| --- |
| [**Read Janet’s statement in full**](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=9d744f5015&e=d19e9fd41c)  |

 |
|

|  |
| --- |
|  |

 |
|

|  |  |
| --- | --- |
|

|  |
| --- |
| **In case you missed it: Rivaroxaban Tablets – Reimbursement Changes Effective September 2024**Starting next month, Rivaroxaban tablets (2.5mg, 10mg, 15mg, and 20mg) will be reclassified outside of Category C, which impacts on their reimbursement. The reimbursement prices will now be based on generic products and calculated using information from suppliers obtained under the Health Service Products (Provision and Disclosure of Information) Regulations 2018.[**L**](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=49f87fc669&e=d19e9fd41c)[**earn more**](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=60e03b715f&e=d19e9fd41c) |

 |

 |
|

|  |
| --- |
|  |

 |
|

|  |  |
| --- | --- |
|

|  |
| --- |
| **Legislation restricting the sale and supply of gonadotrophin-releasing hormone analogues extended**The Government has extended the ban on the sale and supply of Gonadotrophin-Releasing Hormone Analogues until 26th November 2024, with plans to potentially make the ban permanent following a formal consultation.[**Learn more**](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=f4a6d5a20a&e=d19e9fd41c) |

 |

 |
|

|  |
| --- |
|  |

 |
|

|  |  |
| --- | --- |
|

|  |
| --- |
| **Windsor Framework Industry Webinar**The Medicines & Healthcare products Regulatory Agency (MHRA) are hosting webinars for those involved in medicines supply on the Windsor Framework.[The Windsor Framework](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=6cbc91c2bc&e=d19e9fd41c) sets out the long-term arrangements for the supply of medicines into Northern Ireland after Brexit and has led to changes to the Human Medicines Regulations. As part of these measures, from 1st January 2025 all medicines on the UK market will use the same packaging and labelling, and must be labelled as ‘UK Only’.The first MHRA webinar, scheduled for **10.30am on Thursday 19th September**, aims to help attendees understand the latest guidance and identify any relevant changes they may need to make in preparation for the Windsor Framework implementation date.Pre-submitted questions are encouraged, and a recorded version will be available for those who are unable to attend.[**Learn more and register**](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=19d7530b07&e=d19e9fd41c) |

 |

 |
|

|  |
| --- |
|  |

 |
|  |
|

|  |
| --- |
|  |

 |
|

|  |
| --- |
| Community Pharmacy England banner |

 |
|

|  |
| --- |
|  |

 |

 |
|

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|

|  |  |  |
| --- | --- | --- |
|

|  |  |
| --- | --- |
|

|  |
| --- |
| Twitter |

 |

 |

 |

|  |  |  |
| --- | --- | --- |
|

|  |  |
| --- | --- |
|

|  |
| --- |
| Facebook |

 |

 |

 |

|  |  |  |
| --- | --- | --- |
|

|  |  |
| --- | --- |
|

|  |
| --- |
| LinkedIn |

 |

 |

 |

|  |  |  |
| --- | --- | --- |
|

|  |  |
| --- | --- |
|

|  |
| --- |
| Website |

 |

 |

 |

 |

 |

 |

 |
|

|  |  |
| --- | --- |
|

|  |
| --- |
| **Community Pharmacy England**Address: 14 Hosier Lane, London EC1A 9LQTel: 0203 1220 810 | Email: comms.team@cpe.org.uk*Copyright © 2024 Community Pharmacy England, All rights reserved.*You are receiving this email because you are subscribed to our newsletters. Please note Community Pharmacy England is the operating name of the Pharmaceutical Services Negotiating Committee (PSNC). |

 |

 |

 |

 |

 |

